Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma

NCT00362102 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00362102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00362102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
July 31, 2006
Enrollment
38
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma